Crescent Grove Advisors LLC Takes Position in Prothena Corporation PLC (NASDAQ:PRTA)
Crescent Grove Advisors LLC bought a new stake in Prothena Corporation PLC (NASDAQ:PRTA) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 5,000 shares of the biotechnology company’s stock, valued at approximately $271,000.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in PRTA. Schwab Charles Investment Management Inc. increased its position in Prothena Corporation PLC by 6.4% in the second quarter. Schwab Charles Investment Management Inc. now owns 163,681 shares of the biotechnology company’s stock valued at $8,859,000 after buying an additional 9,824 shares during the period. Sei Investments Co. purchased a new position in Prothena Corporation PLC during the second quarter valued at $176,000. Russell Investments Group Ltd. increased its position in Prothena Corporation PLC by 181.6% in the second quarter. Russell Investments Group Ltd. now owns 33,876 shares of the biotechnology company’s stock valued at $1,834,000 after buying an additional 21,846 shares during the period. Barometer Capital Management Inc. purchased a new position in Prothena Corporation PLC during the second quarter valued at $373,000. Finally, Aperio Group LLC increased its position in Prothena Corporation PLC by 15.8% in the second quarter. Aperio Group LLC now owns 5,043 shares of the biotechnology company’s stock valued at $273,000 after buying an additional 687 shares during the period.
Prothena Corporation PLC (PRTA) opened at 57.16 on Friday. Prothena Corporation PLC has a 12 month low of $40.58 and a 12 month high of $69.53. The stock’s market capitalization is $2.19 billion. The company’s 50-day moving average is $60.52 and its 200-day moving average is $54.91.
Prothena Corporation PLC (NASDAQ:PRTA) last announced its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.89) by $0.43. The firm had revenue of $26.81 million for the quarter, compared to the consensus estimate of $16.08 million. Prothena Corporation PLC had a negative net margin of 527.56% and a negative return on equity of 33.20%. The business’s quarterly revenue was up 7951.1% on a year-over-year basis. During the same period last year, the company posted ($1.18) EPS. Equities analysts anticipate that Prothena Corporation PLC will post ($4.54) earnings per share for the current year.
WARNING: This article was published by Daily Political and is the property of of Daily Political. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at https://www.dailypolitical.com/2017/08/12/crescent-grove-advisors-llc-takes-position-in-prothena-corporation-plc-nasdaqprta.html.
Several research analysts have recently weighed in on the stock. Zacks Investment Research raised shares of Prothena Corporation PLC from a “hold” rating to a “buy” rating and set a $66.00 target price on the stock in a research report on Friday. BidaskClub downgraded shares of Prothena Corporation PLC from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Jefferies Group LLC assumed coverage on shares of Prothena Corporation PLC in a research report on Monday, July 10th. They issued a “buy” rating and a $100.00 target price on the stock. Oppenheimer Holdings, Inc. reissued an “outperform” rating and issued a $70.00 target price on shares of Prothena Corporation PLC in a research report on Thursday, July 6th. Finally, ValuEngine raised shares of Prothena Corporation PLC from a “sell” rating to a “hold” rating in a research report on Thursday, June 15th. One equities research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $77.09.
In other Prothena Corporation PLC news, insider Karin L. Walker sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, July 17th. The shares were sold at an average price of $64.89, for a total transaction of $324,450.00. Following the sale, the insider now directly owns 5,000 shares in the company, valued at approximately $324,450. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Dennis J. Selkoe sold 3,500 shares of the firm’s stock in a transaction that occurred on Friday, July 7th. The stock was sold at an average price of $58.11, for a total transaction of $203,385.00. Following the sale, the director now owns 6,345 shares in the company, valued at $368,707.95. The disclosure for this sale can be found here. Company insiders own 3.10% of the company’s stock.
Prothena Corporation PLC Company Profile
Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
Want to see what other hedge funds are holding PRTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Prothena Corporation PLC (NASDAQ:PRTA).
Receive News & Ratings for Prothena Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena Corporation PLC and related companies with MarketBeat.com's FREE daily email newsletter.